The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...